EGFR and non-small cell lung carcinoma: No improvement could be found in the subgroup analysis involving the comparison of the adjuvant first-generation EGFR-TKI group with the chemotherapy group (HR, 0.75; 95% CI, 0.48–1.16, P = 0.189, Fig. 3A), or the placebo group (HR, 0.85; 95% CI, 0.61–1.19; P = 0.345; Fig. 3A) in resected EGFR-mutant NSCLC.